VEGFA and renal cell carcinoma: Unfortunately, the clinical benefit associated with anti-VEGF therapies is often limited, as patients exhibit acquired tumor resistance to VEGF inhibition; thus there is great interest in identifying additional angiogenesis targets that, in combination with anti-VEGF therapies, can lead to more effective treatments for RCC.